fast food on glp 1 As the GLP‑1 boom pushes consumers toward more protein and better nutrition, chains are adapting their menus. Several major chains are already rolling out new menu items and some cost Fast food chains are now

Tirzepatide, a dual GIP/GLP-1 receptor agonist, powers both Mounjaro (diabetes) and Zepbound (weight management)

Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

However, these adjusted thresholds have not been formally incorporated into FDA labeling for GLP-1 medications, creating a significant gap where Asian patients may have clear metabolic indications for treatment but fail to meet the standard BMI criteria